The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass

“The Human Acellular Vessel® (HAV) is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the U.S. Food and Drug Administration (FDA), the HAV is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.” MORE

Image Credit: Journal of Vascular Surgery